Calif.--(BUSINESS WIRE)--March 10, 2005--Arrowhead
Research Corporation (NASDAQ:ARWR) (NASDAQ:ARWRW)
announced today that it has exclusively licensed new
technology in dip pen nanolithography (DPN) from the
California Institute of Technology (Caltech). In addition,
Arrowhead acquired a 12-month option to exclusively
license additional patent applications from Caltech
covering nanotube-based scanning probes, lipid membrane
fabrication, nanotube-based memory devices, and nanotube
strain sensors, which technology could potentially
be used as mechanically tunable light emitting diodes
(LEDs). During the option period, the Company expects
to craft commercialization plans for these technologies.
"It's great to see our strategy of funding research
in exchange for rights to intellectual property come
full circle," said R. Bruce Stewart, President
of Arrowhead. "Arrowhead and its subsidiaries
now own or have licensed over 240 patents and patent
applications to a range of different materials, devices,
and systems and are looking to strategically add more
patents to our portfolio in the near future."
The licensed technology
(covered by patent applications) relate to the use
of DPN to write different biological molecules on
previously inaccessible, or difficult to pattern,
surfaces. DPN potentially could be used as a research
tool for understanding biomolecular interactions,
as well as in developing and manufacturing nanoscale
diagnostic devices, data storage systems, and molecular-cascade
logic devices. The technology was developed at Caltech
in the labs of Professor C. Patrick Collier, whose
research Arrowhead has been funding since 2003.
About Arrowhead Research
is a development-stage nanotechnology company structured
to bring together a diverse and innovative mix of
technologies, rights to a broad suite of intellectual
property, and some of the most respected minds in
this dynamic field. There are three strategic components
to Arrowhead's business model:
-- The Commercialization
Program: Arrowhead forms or acquires majority-owned
subsidiary companies pursuing products based on nanotechnology
in high-growth technology markets.
-- The Research Program:
Arrowhead funds nanoscience research at universities
in exchange for exclusive rights to license the technology.
-- The IP Toolbox:
Arrowhead acquires, licenses, and sublicenses intellectual
property in nanotechnology.
operates four majority-owned subsidiary companies:
-- Aonex Technologies,
Inc., developing and commercializing proprietary semiconductor
-- Insert Therapeutics,
Inc., developing and commercializing a proprietary
nanoscale drug delivery system.
-- Nanotechnica, Inc.,
developing capabilities for mass-production of a variety
of proprietary nanoscale devices, including laboratory
on a chip.
-- Calando, Inc. is
developing nanostructures for delivery and therapeutic
use of RNA interference.
Arrowhead is funding
three research efforts in nanotechnology at the California
Institute of Technology in the areas of nanomaterials,
nanoelectronics, and nanobiomolecular tools.
Arrowhead Research Corporation
R. Bruce Stewart, 626-792-5549